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MaWhether left ventricular noncompaction (LVNC) is a distinct cardiomyopathy or a morphologic trait shared by different
cardiomyopathies remains controversial. Current guidelines from professional organizations recommend different stra-
tegies for diagnosing and treating patients with LVNC. This state-of-the-art review discusses new insights into the basic
mechanisms leading to LVNC, its clinical manifestations, treatment modalities, anatomy and pathology, embryology,
genetics, epidemiology, and imaging. Three markers currently deﬁne LVNC: prominent left ventricular trabeculae,
deep intertrabecular recesses, and a thin compacted layer. Although new genetic data from mice and humans supports
LVNC as a distinct cardiomyopathy, evidence for LVNC as a shared morphological trait is not ruled out. Criteria supporting
LVNC as a shared morphological trait may depend on consensus guidelines from the multiple professional organizations.
Enhanced imaging and increased use of genetics are both predicted to signiﬁcantly impact our overall understanding of
the basic mechanisms causing LVNC and its optimal management. (J Am Coll Cardiol 2014;64:1840–50) © 2014 by the
American College of Cardiology Foundation.L eft ventricular noncompaction (LVNC) is de-ﬁned by 3 markers: prominent left ventric-ular (LV) trabeculae, deep intertrabecular
recesses, and the thin compacted layer (1). The
spectrum of morphologic variability is extreme,
ranging from hearts with a nearly absent compacted
layer and an almost exclusively trabecular compo-
nent in the LV apex, to hearts with prominent
trabeculae and deep alternating recesses, but a
well-represented compacted layer. Whether LVNC
is a distinct cardiomyopathy or a morphologic trait
shared by different types of cardiomyopathies is
still debated. LVNC can be isolated or associated
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criteria.
The LVNC trait may be familial (inherited) or
nonfamilial (sporadic). Nonfamilial forms are diag-
nosed when LVNC is proven absent in relatives (5).
Sporadic LVNC can be acquired, as in highly-trained
athletes (6), sickle cell anemia patients (7), and
pregnancy (8). In the pregnancy study by Gati et al.
(8), 73% of affected women demonstrated complete
resolution of the trabeculation during post-partum
follow-up (8). In some cases, the trabeculation
phenotype may occur in response to a mechanical
load, and may disappear as the mechanical load
dissipates. It is not known if there is a genetic un-
derpinning to the disease in these cases (6–8).
Cases in children suggest that 75% have electrocar-
diogram abnormalities, and most have depressed
systolic function (9). Some children have transient
recovery followed by later deterioration, suggesting
that these cases in children are genetic in nature.
The genetic bases of familial LVNC are still a matter
of research. Most familial cases identiﬁed to date
are associated with mutations in the same genes
that cause other types of cardiomyopathies (10,11).
Whether these disease genes cause the cardiomy-
opathy or the LVNC phenotype remains to be clari-
ﬁed (12). A limitation of many (but not all) of these
genetic studies is that most only screened genes
associated with other cardiomyopathies, such as
sarcomeric genes, which are also associated with
hypertrophic cardiomyopathy (HCM), restrictive
cardiomyopathy (RCM), and dilated cardiomyopathy
(DCM).
Although there is no current gold standard for
LVNC diagnosis, cardiac imaging is the best tool
currently available. Pathoanatomic investigation in
autopsy hearts or in hearts excised at transplantation
provides data for pathoimaging correlations and
assessment of imaging-based diagnoses (13). The most
commonly used imaging modalities include echo-
cardiography and cardiac magnetic resonance (CMR).
Echocardiography provides the basic tool for diag-
nosis (14), whereas CMR adds anatomic details and
functional information on kinesis of the non-
compacted versus compacted segments and ﬁbrosis
(15). The limitations of imaging will be discussed.
Clinical management is based on the functional
phenotype and related complications. The manage-
ment of atrial and ventricular arrhythmias, device
implantation, resynchronization, ablation proce-
dures, and even LV surgical remodeling has been a
matter of speciﬁc attention, raising the question
of whether LVNC deserves speciﬁc medical strate-
gies (4,16).EMBRYOGENIC AND
NONEMBRYOGENIC HYPOTHESES
There can be multiple etiologic bases of
LVNC: it may occur as an isolated trait or
disease (I-LVNC); in association with genetic
diseases and congenital defects; be sporadic
and acquired in physiological (6) or patho-
logic conditions (7); or be permanent or
transient (8). Therefore, LVNC can originate
during embryonic development or be ac-
quired later in life.
NONEMBRYOGENIC HYPOTHESIS. Emerging
evidence supports the hypothesis that the
pathogenetic mechanisms leading to non-
compaction or increased trabeculation may
occur in adult life, leading to acquired LVNC.
In young athletes, increased LV trabeculation
may represent the effect of cardiac remodel-
ing (6); in this case, trabeculation becomes
more prominent, but the compacted layer is well
represented. It has been suggested that “following
ECG and echocardiography, 0.9% of highly trained
athletes demonstrate concomitant T-wave inversion
and reduced baseline indices of systolic function that
may be considered diagnostic of LVNC” (6). The de
novo LV trabeculations observed in a signiﬁcant
proportion (>25%) of pregnant women suggest that
LV trabeculations may occur in response to increased
LV loading conditions or other physiological adapta-
tion mechanisms related to pregnancy (8). The
increased trabeculation observed in individuals with
sickle cell anemia may represent an exaggerated
myocardial response to the increased cardiac pre-load
(7). In summary, this evidence supports the hypoth-
esis that particular phenotypic characteristics of
LVNC are identiﬁed in cases including pregnancy,
sickle cell anemia, and athletes.
EMBRYOGENIC HYPOTHESIS. Most data supporting
the embryogenic hypothesis of LVNC come from ex-
perimental studies. Fetal echocardiographic studies
may contribute to elucidation of the embryogenic
mechanisms of LVNC and its association with other
cardiac diseases. In a very elegant study by Aruna-
mata et al. (17), 22 of 24 fetuses with LVNC had
congenital heart disease, and 15 had complete heart
block. Studies in identical twins may further expand
the routes of investigation, especially when identical
phenotypes are expected, but not observed (18).
Studies in experimental models suggest that the
process of cardiac trabeculation begins after the car-
diac looping stage. Trabeculae formation begins with
the emergence of myocytes through delamination
FIGURE 1 Two Hearts Depicting the Variability in Both
Extension and Depth of Trabeculae and Recesses
(A) In this high-magniﬁcation view of the apical wall of the heart,
the noncompacted area is limited to a few apical trabeculae. The
patient harbored mutations p.(Arg495Trp) in myosin binding
protein cardiac 3 (MYBPC3) and p.(Asp117Asn) in Lim domain
binding protein 3 (LDB3) genes (MHþD OH GAD EG-MYBPC3
[p.Arg495Trp]þLDB3 [p.Asp117Asn]SC-IV). Although LBD3 is a candidate
gene for LVNC, in this family, the disease segregated with the
mutation in MYBPC3. (B) In this heart, the prominent trabecu-
lations (blue line) and deep recesses (red line) involve the
entire left ventricular apex.
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Emerging evidence suggests that the myocytes
forming the trabeculae arise from a different clonal
origin in the heart wall (19,20). Myocytes project
radially into the cavity and are covered by the endo-
cardial layer. This array guarantees the best perfusion
of the myocytes by increasing the contact surface
between the left ventricular cavity and the myocytes,
while the coronary tree is not yet developed. In-
tertrabecular spaces are transformed into capillary
vessels. Failure at this stage corresponds to the for-
mation of thin elongated trabecular projections
separated by deep recesses. The compact layers of
myocytes proliferate, and the epicardium enters the
myocardial wall and forms the coronary vasculature
(21,22). Recent studies in zebraﬁsh and mice suggest
that cardiac trabeculation is mediated by endocardial
neuregulin 1 through the ErbB4 and ErbB2 receptor
complex (19,23–27). Deletion or mutation of the
homologs of Drosophila mindbomb 1 (MIb1), Notch1,
neuregulin 1, Erbb4, or Errb2 in zebraﬁsh or mice
results in the absence of trabecular formation. ErbB3
activation by Neuregulin 1 phosphorylates focal ad-
hesion kinase (FAK). Systemic deletion of FAK in
mice also results in a phenotype similar to LVNC
(28,29). Thus, neuregulin 1 signaling through ErbB4
and ErbB2 leading to FAK phosphorylation appears
integral to cardiac trabecular formation. Moreover,
Notch signaling in the endocardium is also critical
for cardiac trabecular formation (30,31).
As cardiac development progresses, myocytes
compact by organizing into ordered bundles that
progressively generate the compacted myocardial
walls (more prominent in the left than in the right
ventricle). The trabecular portion of the myocardial
wall is tiny and thinner in the LV than in the right
ventricle, and the compacted wall is more prominent
in the thicker LV wall. Two embryologic morphoge-
netic hypotheses were formulated as potential ex-
planations of LVNC pathogenesis. Hypothesis 1 states
that arrested or abnormal myocardial morphogenesis
leading to LVNC occurs during heart development,
when myocyte organization fails to evolve from the
embryonic spongiform condition to the compacted,
mature state. Although both ventricles may be
involved, the LV is generally affected (32). Hypothesis
2 states that LVNC occurs as a result of inhibiting the
regression of embryonic structures (33). Sponginess
would result from the looseness of cells or of cell
bundles. LVNC describes a macroscopic mismatch
between the noncompacted trabeculae and the com-
pacted myocyte layers. Myocytes in the trabeculae do
not show histologic differences from those forming
the compacted layer, which explains why LVNChistology (i.e., endomyocardial biopsy) does not
speciﬁcally contribute to the diagnosis. The diag-
nostic hallmark of LVNC is the macroscopic appear-
ance that correlates with imaging ﬁndings.
ANATOMY AND PATHOLOGY
In hearts excised at transplantation or at autopsy,
LVNC diagnosis is on the basis of the prominent
appearance of LV trabeculae and the ratio between
the compacted and noncompacted LV wall (13).
Sectioning of formalin-ﬁxed hearts provides the
best way of measuring compacted and noncom-
pacted layers (34). Prominent trabeculae and thin,
compacted myocardial layers can be described either
FIGURE 2 High-Magniﬁcation View of Intertrabecular
and Endocardial Thrombotic Stratiﬁcation
Intertrabecular thrombotic stratiﬁcation is indicated by a
blue arrow, and endocardial thrombotic stratiﬁcation by a
green arrow.
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when the noncompacted/compacted ratio does not
meet that commonly used (2.3) in imaging diagnosis
(35). The pathologic diagnosis should not be forced
into imaging criteria, but should provide data for a
pathology-imaging correlation (Figure 1). Imaging is
especially useful for identifying mural thrombi
wedged within the intertrabecular recesses (espe-
cially common in hypokinetic LVs) (Figure 2).
LV dilation and LV hypertrophy can be present or
absent and do not inﬂuence LVNC diagnosis. Given
the common localization of the noncompacted areas
in the apex and the common localization on LV hy-
pertrophy at the septum, the 2 diagnoses of HCM and
LVNC can coexist. The topographic distribution of
LVNC does not typically extend to the interventric-
ular septum, although the septum may be involved in
rare cases. LVNC has also been described in associa-
tion with RCM. In pure RCM, the enlarged atria and
the small nonhypertrophic ventricles support the
pathologic diagnosis. The “restriction” is a functional
diagnostic clue that can be inferred in pathologic
studies by the atrial/ventricular size mismatch in the
absence of signiﬁcant LV hypertrophy. LVNC may
also coexist with arrhythmogenic right ventricular
cardiomyopathy (ARVC). In classical ARVC without
involvement of the LV, the presence of LVNC is in-
dependent of the right side cardiomyopathy. In this
context, the causes of ARVC and LVNC may not
coincide. In biventricular and predominantly leftarrhythmogenic cardiomyopathies, the presence of
LVNC may be considered either as an independent
trait or as part of the arrhythmogenic cardiomyopathy
involving the LV. The pathology study should
contribute to characterization of LVNC as an isolated
ﬁnding or as a trait present in cardiomyopathy in
autopsied hearts and in hearts excised at trans-
plantation. Finally, ﬁbrous endocardial thickening
can be present; it may reﬂect the effect of volume
overload in LVNC in DCM or the organization pattern
of mural thrombi. Overall, LVNC can be observed in
all types of cardiomyopathies.
EPIDEMIOLOGY
LVNC occurs in infants (0.81 per 100,000 infants/
year), children (0.12 cases per 100,000 children/year)
(21), and adults (prevalence 0.014%) (33). It can occur
as an isolated myocardial trait or be associated with
cardiomyopathies (hypertrophic, restrictive, dilated,
and arrhythmogenic), congenital heart diseases (36),
and complex syndromes affecting multiple organs
and tissues, including mitochondrial diseases caused
by mutations in both nuclear (23) and mitochondrial
genes (24). In isolated LVNC, the intertrabecular re-
cesses communicate with the LV cavity. LVNC was
ﬁrst described in 1984, in Engberding and Bender’s
(37) description of the ﬁrst echocardiographic diag-
nosis of persistence of isolated myocardial sinusoids.
In patients with LVNC associated with other congen-
ital heart diseases, the deep intertrabecular recesses
communicate with both the LV cavity and the coro-
nary circulation (33). LVNC was ﬁrst described by
Bellet and Gouley (38) in 1932, when they observed
abnormally “spongy” myocardial walls associated
with aortic atresia and coronary-ventricular ﬁstula
in an autopsy of a newborn with congenital heart
disease.
By itself, “LVNC” does not necessarily describe
a disease; it describes an anatomic variant of LV
structure (39,40). There is wide variability in the ratio
between trabeculated and compacted layers of the
LV. At 1 extreme, severe forms of LV apex non-
compaction and inferior/lateral walls are typically
seen in children with Barth syndrome. In these pa-
tients, LVNC is associated with LV dilation and
dysfunction (41). At the other extreme, hyper-
trabeculation with prominent (but less pronounced)
trabeculations and intertrabecular recesses associ-
ated with a preserved, compacted layer is more
common. Ethnic differences in the amount of trabe-
culation have been observed; Gati et al. (6) suggested
prominent LV trabeculation was more prevalent in
African-American subjects.





MIM Number Additional Phenotypes
Mode of
Inheritance Ref. #
1p36.32 Left ventricular noncompaction 8 615373 PRDM16 605557 Dilated cardiomyopathy Autosomal
dominant
(77)
1q32.1 Left ventricular noncompaction 6 601494 TNNT2 191045 Dilated cardiomyopathy Autosomal
dominant
(78)
10q23.2 Left ventricular noncompaction 3 601493 LDB3 605906 Dilated cardiomyopathy Autosomal
dominant
(79)
11p15 Left ventricular noncompaction 2 609470 None 609470 — Autosomal
dominant
(80)
11p11.2 Left ventricular noncompaction 10 615396 MYBPC3 600958 Dilated cardiomyopathy Autosomal
dominant
(81)
14q11.2 Left ventricular noncompaction 5 613426 MYH7 160760 Dilated cardiomyopathy Autosomal
dominant
(80,82)
15q14 Left ventricular noncompaction 4 613424 ACTC1 102540 Dilated cardiomyopathy Autosomal
dominant
(83)
15q22.2 Left ventricular noncompaction 9 611878 TPM1 191010 Dilated cardiomyopathy — (81)
18q11.2 Left ventricular noncompaction 7 615092 MIB1 608677 — Autosomal
dominant
(30)










This table was adapted from Online Mendelian Inheritance in Man (OMIM). Additional information is available at the OMIM website (85). From left to right, the table provides the location for
each locus, the phenotype (with a number that refers to phenotypes associated with the particular genes or loci), the phenotype MIM number, gene/locus, the gene/locus MIM number,
additional phenotypes, mode of inheritance, and references. MIM number refers to a numerical assignment for genes and functional segments of deoxyribonucleic acid, as well as to inherited
diseases. X-linked recessive indicates that both matching genes must be abnormal to cause the disease.
ACTC1 ¼ actin, alpha, cardiac muscle; DTNA ¼ dystrobrevin alpha; LDB3 ¼ Lim domain-binding 3; LVNC ¼ left ventricular noncompaction; MIB1 ¼ homolog of Drosophila mindbomb;
MYBPC3 ¼myosin-binding protein C, cardiac; MYH7 ¼myosin heavy chain 7, cardiac muscle, beta; PRDM16 ¼ PR domain–containing protein 16; TAZ ¼ tafazzin; TNNT2 ¼ troponin T2; TPM1 ¼
tropomyosin 1.
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This paper’s title posed the question of whether LVNC
is a “distinct cardiomyopathy or a trait shared by
different cardiac diseases.” Human genetic studies
suggest that several genes are associated with LVNC
(Table 1).
Nearly all of the genes associated with LVNC are
associated with additional phenotypes, like cardio-
myopathies or congenital heart defects. However,
mutations in 1 gene, MIB1, segregated with auto-
somal dominant LVNC in 2 Spanish families, and a
conditional loss-of-function allele in a mouse also led
to LVNC (30). The hypertrabeculation and non-
compaction seen in the MIb1 mouse was mimicked in
a mouse with inactivation of Jagged1 in the myocar-
dium or Notch1 in the endocardium, suggesting that
the Notch1 signaling pathway was, indeed, involved
(30). Chen et al. (31) recently reported an important
role in trabeculation for endocardial expression of a
Notch ligand, Fkbp1a. These ﬁndings ﬁrmly support
the hypothesis that in some circumstances, LVNC is a
cardiomyopathy, and dysregulated Notch signaling in
the endocardium leads to disrupted trabeculation.
Barth syndrome is an X-linked recessive disorder
that is diagnosed either pre-natally or in infants and is
characterized by failure to thrive, growth retardation,and cardiovascular abnormalities including LVNC
(5,42). It is probably 1 of the few cardiomyopathies
that can be pre-natally recognized with imaging (42),
and typically includes hypokinetic DCM with LVNC
that can cause death in early infancy. Barth syndrome
is associated with the gene G4.5, encoding tafazzin
(TAZ), a mitochondrial protein critical for remodeling
of the phospholipid, cardiolipin. TAZ knockdown
mice die embryonically with cardiomyopathy charac-
terized by hypertrabeculation and noncompaction
(43). The mouse model together with human TAZ
and Barth syndrome data provide additional evidence
that genetic pathways can lead directly to hyper-
trabeculation and noncompaction, suggesting that
in some instances, LVNC is a cardiomyopathy (30,44).
Other LVNC-associated genes in Table 1 are also
associated with additional phenotypes, including
cardiomyopathies (45). LVNC lacks genome-wide as-
sociation studies for LVNC, which would be chal-
lenging, given that patients present with pleiotropic
phenotypes (46). Additional limitations include that
most studies reported to date are underpowered,
limiting their strength. Although whole-genome and
-exome sequencing permit the discovery of a new
complexity of genotypes (46), many studies reported
to date do not report clinical whole-genome or







• CK-MM (creatine 
kinase-MM isoform)
(at initial evaluation only)
of LVNC patients:
Clinical screening every
3 years beginning in 
childhood
clinical screening is 
recommended yearly
in childhood and every 
1−3 years in adults
Echocardiographic diagnosis of LVNC in probands
Cardiac magnetic resonance (CMR) 
Family history and echocardiographic screening of relatives
and/or determining potential development in family members)
Genetic testing
in probands:
• Clinically guided in case of suspected syndromes/diseases 
typically showing LVNC (ie. Barth Syndrome)
• Testing for genes known to be associated with LVNC
in relatives:
of mutation in the proband
• Segregation studies in the family
Depending on the 
phenotype, patients are 
managed according to







CENTRAL ILLUSTRATION A Clinical Management Outline for LVNC
Diagnosis and screening strategies for probands and relatives are listed in the left panel, clinical monitoring guides are listed in the middle
panel, and treatment options are outlined in the right panel. Data for this table was selected from the Online Mendelian Inheritance in Man
(85), established as a collaboration between the Institute of Genetic Medicine, Johns Hopkins Medicine, and the National Human Genome
Research Institute. ICD ¼ implantable cardioverter-deﬁbrillator; LVNC ¼ left ventricular noncompaction.
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phenotypes like LVNC requires criteria for pheno-
typing and quality control for genotyping. Thus,
at this early stage, we cannot rule out modiﬁer genes
or the potential for several genes to inﬂuence the
LVNC phenotype. Epigenetic (i.e., deoxyribonucleic
acid methylation) or environmental causes, such as
increased mechanical load or stress that may induce
the phenotype, are additional possibilities. A recent
study using high-resolution episcopic microscopy and
3-dimensional reconstruction shows (with high
sensitivity and quantiﬁcation) hypertrabeculation in
the MIb1 loss-of-function allele mouse, compared
with a wild-type mouse (47).
The Central Illustration outlines LVNC manage-
ment. In the left panel, under diagnosis, we suggest
imaging for the initial diagnostic tool in the proband.
To conﬁrm diagnosis or determine potential in-
volvement in family members, family history and
echocardiographic screening are 2 potential options.
In cases of suspected syndromes, such as Barth syn-
drome (an X-linked recessive disorder), genetic
testing in probands is suggested, given the relatively
high fatality rate. Genetic testing in relatives is an
additional option after the mutation in the proband is
identiﬁed.
Clinical monitoring options in probands (Central
Illustration, middle panel) include physical ex-
amination, electrocardiogram, echocardiogram, and
creatine kinase MM isoform. For monitoring of ﬁrst-degree relatives, options include clinical screening
every 3 years beginning in childhood and, if amutation
is identiﬁed, annual clinical screening in children and
every 1 to 3 years in adults.
Treatment and management options are listed
in the far right panel of the Central Illustration
and depend entirely on the patient’s phenotype
and clinical needs and the corresponding guide-
lines (see Management section). Three topics will
be touched on: oral anticoagulation medicine,




is the ﬁrst diagnostic tool for LVNC in both index
patients and family members. Two-dimensional
grayscale echocardiography is the most common
and useful tool for LVNC diagnosis, showing both
broad trabeculae and deep intertrabecular recesses
in the LV myocardium, typically located in the LV
apex and the midinferior and lateral walls. In
contrast, the basal and midinterventricular septum
scanned by an apical 4-chamber view is typically
free of trabeculae (Figure 3). In most patients, it is
necessary to image the LV not only with standard
deﬁned imaging views, but also with atypical views
to image the more apical segments of the LV and
detect the prominent trabeculae (Figure 4).
FIGURE 3 Echocardiographic 4-Chamber Views Distinguishing
Prominent Trabeculation Versus Hypertrabeculation
(A) An echocardiographic 4-chamber view from a patient with a dilated cardiomyopathy
presenting with prominent trabeculation in the left ventricular (LV) apex and lateral
wall. In this case, the criteria for left ventricular noncompaction (LVNC) are not fulﬁlled.
(B) An echocardiographic 4-chamber view from a patient with a typical LVNC presenting
with hypertrabeculation in the LV apex and lateral wall.
FIGURE 4 Echocar
(A) In the echocardio
illustrate the noncom
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isolated LVNC are available (48–51), but none can be
considered the gold standard for LVNC diagnosis.
Furthermore, the criteria are indirect, assessing
morphological abnormalities. After careful evaluation
of all criteria, the most important echocardiographic
criterion remains a noncompacted/compacted ratio
>2.0 in end-systole (49,50). However, when using this
ratio to diagnose LVNC, one must keep its quite high
interobserver and intraobserver variability in mind as
a limitation. Importantly, for LVNC diagnosis, the
aforementioned imaging criteria may be considered
together with family history and genetics.diographic and Color Doppler Images From a Patient With LVNC
graphic image, an atypical 4-chamber view was used to better
paction in the LV apex. (B) The same view with color Doppler
ighlights perfusion of intertrabecular recesses from the LV cavity.
igure 3.In addition to morphological abnormalities, systolic
dysfunction is frequently present in LVNC hearts. It
was hypothesized that small vessel “dysfunction”
with impaired coronary ﬂow reserve and microcircu-
latory defects, together with a primary myocardial
disease, is responsible for the functional abnormal-
ities (52). Thus, in classical LVNC cases, especially in
advanced stages, both hypokinetic and akinetic re-
gions can be detected in the diseased segments by
wall motion analysis. Recent studies suggest that
deformation imaging could better reveal systolic
impairment in patients with LVNC, even in those
with preserved LV ejection fraction (53,54). In addi-
tion, a tissue Doppler-derived strain rate study de-
monstrated a distinct deformation pattern in LVNC,
with signiﬁcantly higher longitudinal systolic strain
rate and strain in the basal segments than in the apex,
which could help differentiate LVNC from DCM (55).
Diastolic dysfunction is another typical echocar-
diographic feature of LVNC. Thus, most patients
(even children) present with abnormal diastolic ﬁlling
parameters (56). Diastolic dysfunction is attributed in
part to abnormal relaxation resulting from extensive
trabeculation (57).
CONTRAST ECHOCARDIOGRAPHY. In obese patients
or patients with lung disease who may have poor
acoustic windows, conventional echocardiography
has diagnostic limitations. In these cases, the diagnosis
is often missed because of imaging quality limitations,
especially in the more apical region of the heart.
Echocardiographic contrast imaging with various
contrast agents enhances endocardial border deﬁni-
tion and could improve detection of this rare cardio-
myopathy, which could otherwise be misdiagnosed
(58,59). Thus, when conventional echocardiographic
images are poor or diagnosis is uncertain, contrast
echocardiography can be helpful.
CARDIAC MAGNETIC RESONANCE. CMR may help to
accurately describe and diagnose LVNC and distin-
guish true LVNC from the prominent hypertrabe-
culation that can be seen in normal hearts and
individuals (Figure 5) (60). The major advantage of
CMR is that a 3-dimensional dataset with equal image
quality can be acquired. Thus, potential trabeculae at
any region cannot be missed. The major marker is
(as for echocardiography) the presence of several
prominent trabeculations in the LV with topographic
involvement of apical and mid segments of the lateral
and inferior walls. Prior studies were performed
in small clinical series (61,62). A noncompacted/
compacted ratio >2.3 on CMR is considered the
cutoff for LVNC diagnosis (Figure 6) (61). This crite-
rion yielded >43% of positive subjects in MESA
FIGURE 5 CMR From a Patient With Ischemic Heart Disease
and Ejection Fraction of 27%
Apart from the ischemic heart disease history, this patient does not meet the cardiac
magnetic resonance (CMR) criteria for LVNC cardiomyopathy. (A) Short-axis view showing
the papillary muscle with prominent trabeculation in mid-LV segments. (B) Long-axis view
showing trabeculation mainly in LV lateral segments. Abbreviations as in Figure 3.
FIGURE 6 CMR From a Patient With LVNC
(A) Short-axis view showing the hypertrabeculation in all mid-LV segments apart from the
interventricular septum. (B) Long-axis view showing the hypertrabeculation mainly in the
apical and mid-LV segments. Abbreviations as in Figures 3 and 5.
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tantly, to avoid misdiagnosis, compact papillary
muscle should be distinguished from prominent tra-
beculations, which is quite easy to do with the 3-
dimensional dataset acquired during CMR.
Fractal analysis was also used to quantify LV
trabeculae (15). In a recent study of 30 patients, the
combination of end-diastolic measurements at basal,
mid, and apical segments was found to be the best
selector of LVNC cases from the normal population
(63). When grouping patients according to normal and
reduced ejection fraction, interpretation of the data
was challenged by the unanswered question of
whether normal and low ejection fraction groups
simply represent 2 phases of the same condition
diagnosed at different evolutionary stages, or
whether they represent the phenotypes of different
diseases. The authors concluded that “A gold stan-
dard for the diagnosis of LVNC continues to be lack-
ing as no imaging or pathology signature has yet
been agreed” (64). While waiting for the ideal deﬁ-
nition and diagnostic criteria, a descriptive diagnosis
including both LVNC and the LV morphofunctional
phenotype (e.g., DCM-like, HCM-like) can be adopted
to collect data from emerging series.
The typical 2-layered structure of the LV wall can be
better measured in CMR, where the thinner, com-
pacted layer can be precisely measured in affected
ventricular segments. As in echocardiography, func-
tional data (hypokinesis of the noncompacted seg-
ments vs. normal kinesis of unaffected segments) may
further strengthen the diagnostic hypothesis.
Advanced CMR modalities can provide additional
information. For example, high-intensity endocardial
T2 signals, subendocardial perfusion defects, and
delayed enhancement of the subendocardial layer can
add information about function and ﬁbrosis of the
affected segments and the possibility of assessing
whether abnormalities coincide with noncompacted
versus compacted segments (65,66). Advances in im-
aging are contributing to the ability to distinguish
pathologic LVNC from nonpathologic hypertrabe-
culation. The correct diagnosis may prevent unneeded
restrictions for athletes (61). A current gap is the
inability to establish the thickness and functionality of
the thin, compacted LVNC heart layers. This knowl-
edge may lead to improved clinical management.
MANAGEMENT OF LVNC
There are no speciﬁc guidelines for management of
LVNC. Management includes conﬁrmation of the
echocardiographic or CMR diagnosis. Differential
diagnoses include prominent hypertrabeculationwith normal compacted LV layer, apical HCM, DCM,
endocardial ﬁbroelastosis, and LV apical thrombus.
Clinical management of LVNC depends on the
presence or absence of cardiac dysfunction or ar-
rhythmias. Patients with normal LV size and function
undergo clinical monitoring, whereas symptomatic
patients with LV dilation and dysfunction or hyper-
trophy may be clinically managed according to
phenotype. Guidelines suggest that familial LVNC
should be diagnosed by echocardiographic screening
of family members (45). Echocardiographic screening
is recommended for family members, given that the
symptoms are variable and the risks include heart
failure and sudden cardiac death. Genetic testing for
LVNC does not change clinical management of the
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1848disease; however, it may be helpful for conﬁrming
diagnoses in family members and/or determining
potential development in family members to aid in
the timing of screening (Central Illustration) (67).
Clinical monitoring may include clinical history,
physical examination, echocardiography, Holter
monitoring, and measurement of high-sensitivity
troponin (Central Illustration).
Currently, there are no speciﬁc treatments for
LVNC. Depending on the phenotype, patients are
managed according to their clinical needs and corre-
sponding guidelines (e.g., for congestive heart fail-
ure, arrhythmias). Oral anticoagulation is a debated
issue in subjects with normal LV function and
absence of LV hypertrophy: patients are either
treated on the basis of the phenotype (oral anti-
coagulation given independently on arrhythmias or
LV dysfunction for primary prevention of embolic
episodes) or in the presence of LV dysfunction, ar-
rhythmias, prior embolic events, or proven atrial or
ventricular thrombi.
Complications with LVNC include heart failure,
arrhythmias including sudden cardiac death, and
systemic embolic events (16). Atrial tachycardia and
ﬁbrillation are common. Ventricular tachyarrhyth-
mias have been reported in up to 47% of symptomatic
patients referred to a tertiary referral center, and SCD
has been reported in 13% to 18% of (mostly adult)
patients with LVNC. Whether the risk of ventricular
arrhythmias is higher than that seen in patients with
corresponding functional phenotypes (DCM, HCM,
and so forth) is not clear. As anticipated (68), LVNC
has been considered a reason to restrict athletic
participation (33,69,70). However, a 48.6  14.6-
month follow-up in athletes fulﬁlling LVNC criteria
did not reveal adverse events (6), thus caution is
advised before introducing restrictions based on iso-
lated LVNC.
It is unknown whether or not the small compacted
layer and the deep recesses of the heart in patients
with LVNC increases the risk of complications, such
as ventricular perforation in interventional occasions
or implantation of devices. This issue is not governed
by guidelines, and decisions may be eventually sup-
ported by tailored evaluations of families, including
evidence of sudden death in affected relatives. In 30
patients with LVNC who underwent implantable
cardioverter-deﬁbrillator (ICD) insertion for second-
ary or primary prevention, 11 patients (37%) had
appropriate ICD therapies in a mean follow-up period
of 40  34 months: 3 with antitachycardia pacing, 4
with ICD shocks, and 4 with both antitachycardia
pacing and ICD shocks (69). Although clinical pre-
dictors for appropriate ICD therapy are not available,this single study suggests that ICD therapy may be
effective in patients with LVNC. Cardiac resynchro-
nization therapy improves New York Heart Associa-
tion functional class in patients with LVNC and may
hence be considered in patients with an LV ejection
fraction #35% and signs of ventricular dyssynchrony
(71,72). More studies need to be completed to deter-
mine the safety and efﬁcacy of the use of ICDs in
patients with LVNC.
SUMMARY AND CONCLUSIONS
In summary, evidence that LVNC is a cardiomyopa-
thy includes the following: 1) speciﬁc mutations in
genes in the Notch1 pathway in mice and humans
leading to dysregulated signaling and hyper-
trabeculation and noncompaction; and 2) speciﬁc
mutations in G4.5 in mice and humans disrupting the
TAZ protein leading to dysregulated remodeling of
cardiolipin and Barth syndrome, characterized by
hypertrabeculation and noncompaction in utero and
failure to thrive. In contrast, evidence that LVNC is a
trait shared by multiple cardiac diseases has not
been ruled out. The data presented on mechanical
load from pregnancy and athletes is compelling.
However, Notch1 signaling is involved in mechano-
sensation (73–75), suggesting that individuals who
develop LVNC may have an underlying mutation in a
gene that disrupts Notch signaling or in other
endocardially-expressed mechanosensing genes. In
these patients, an additional modiﬁer, such as stress
or increased load, may be needed for the phenotype
to present.
Although echocardiography and CMR are useful
for LVNC diagnosis, these approaches are indirect
and present limitations of interobserver and intra-
observer variability. Guidelines for clinical manage-
ment of LVNC suggest that familial LVNC should be
diagnosed by echocardiographic screening of family
members. Genetic testing does not change clinical
management of the disease, but may be helpful for
conﬁrming diagnosis in family members and/or
determining potential development in family mem-
bers to aid in the timing of screening. Anti-
coagulation is the only medication that can be
administered in addition to therapies commonly
used in phenotype-based management of cardiomy-
opathies. We suggest that the American Heart Asso-
ciation, World Health Organization, and the
European Society of Cardiology form a working group
in the near future, and agree on guidelines to spe-
ciﬁcally deﬁne:
1. LVNC as primary pathology, which can be isolated
or associated with cardiomyopathy. It may be
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phenotype and the LVNC (HCM-LVNC, RCM-LVNC,
DCM-LVNC, or ARVC-LVNC) to distinguish I-LVNC
with normal LV size and function.
2. The role of LVNC as a marker for addressing clin-
ical and genetic diagnostic hypotheses.
3. Reproducible and uniﬁed imaging-based diag-
nostic criteria for LVNC.
4. The risk of thrombosis in patients with I-LVNC,
especially when LV size and function are normal.In parallel, to establish real-world data and out-
comes in LVNC patients, we recommend increased
collection of LVNC electronic health record data, with
imaging data and genetic information, if possible (76).
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